Casetta, Cecilia, Oloyede, Ebenezer, Whiskey, Eromona, Taylor, David Michael, Gaughran, Fiona, Shergill, Sukhi S., Onwumere, Juliana, Segev, Aviv, Dzahini, Olubanke, Legge, Sophie E, and others. (2020) A retrospective study of intramuscular clozapine prescription for treatment initiation and maintenance in treatment-resistant psychosis. British Journal of Psychiatry, 217 (3). pp. 506-513. ISSN 0007-1250. (doi:10.1192/bjp.2020.115) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:96379)
The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided. (Contact us about this Publication) | |
Official URL: https://doi.org/10.1192/bjp.2020.115 |
Abstract
BACKGROUND: Clozapine is uniquely effective in treatment-resistant psychosis but remains underutilised, partly owing to psychotic symptoms leading to non-adherence to oral medication. An intramuscular formulation is available in the UK but outcomes remain unexplored.AIMS: This was a retrospective clinical effectiveness study of intramuscular clozapine prescription for treatment initiation and maintenance in treatment-resistant psychosis over a 3-year period.METHOD: Successful initiation of oral clozapine after intramuscular prescription was the primary outcome. Secondary outcomes included all-cause clozapine discontinuation 2 years following initiation, and 1 year after discharge. Discontinuation rates were compared with a cohort prescribed only oral clozapine. Propensity scores were used to address confounding by indication.RESULTS: Among 39 patients prescribed intramuscular clozapine, 19 received at least one injection, whereas 20 accepted oral clozapine when given an enforced choice between the two. Thirty-six (92) patients successfully initiated oral clozapine after intramuscular prescription; three never transitioned to oral. Eight discontinued oral clozapine during the 2-year follow-up, compared with 83 out of 162 in the comparator group (discontinuation rates of 24 and 50, respectively). Discontinuation rates at 1-year post-discharge were 21, compared with 44 in the comparison group. Intramuscular clozapine prescription was associated with a non-significantly lower hazard of discontinuation 2 years after initiation (hazard ratio 0.39, 95 CI 0.14-1.06) and 1 year after discharge (hazard ratio 0.37, 95 CI 0.11-1.24). The only reported adverse event specific to the intramuscular formulation was injection site pain and swelling.CONCLUSIONS: Intramuscular clozapine prescription allowed transition to oral maintenance in an initially non-adherent cohort. Discontinuation rates were similar to patients only prescribed oral clozapine and comparable to existing literature.
Item Type: | Article |
---|---|
DOI/Identification number: | 10.1192/bjp.2020.115 |
Uncontrolled keywords: | Intramuscular clozapine, clozapine, clozapine discontinuation, schizophrenia, treatment-resistant schizophrenia |
Subjects: | R Medicine |
Divisions: | Divisions > Division of Natural Sciences > Kent and Medway Medical School |
Funders: |
National Institute for Health Research (https://ror.org/0187kwz08)
NIHR Imperial Biomedical Research Centre (https://ror.org/01kmhx639) South London and Maudsley NHS Foundation Trust (https://ror.org/015803449) King's College London (https://ror.org/0220mzb33) |
Depositing User: | Rachael Heller |
Date Deposited: | 28 Sep 2022 15:20 UTC |
Last Modified: | 05 Nov 2024 13:01 UTC |
Resource URI: | https://kar.kent.ac.uk/id/eprint/96379 (The current URI for this page, for reference purposes) |
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):